Full-Time
MicroVentures
51-200 employees
Equity crowdfunding platform for investors
No salary listed
Mid
Austin, TX, USA
- 2+ years related work experience in a finance or operations role
- Bachelor’s degree in business or related discipline
- High attention to detail
- Strong organizational skills
- Ability to work in fast-paced environment
- Self-starter
- Highly analytical
- Ability to effectively manage multiple responsibilities
- Assist with the onboarding of secondary sellers and companies to our platform
- Screen sellers/companies to determine if the investment opportunity is a good fit for the platform
- Monitor the deal flow pipeline to determine actionable next steps
- Assist with the collection, preparation, and distribution of transfer documents and other related items
- Prepare company research reports including industry and competitor analysis
- Monitor the secondary market and analyze trends
- Prepare company transfer notices and help facilitate closings weekly
- Work with operations department to set up wires to sellers
- Late stage company analysis
- Market/vertical research
- Staying current on tech industry trends
- Monitoring the venture capital and tech startup landscape
MicroVentures operates an equity crowdfunding platform that allows both accredited and non-accredited investors to invest in high-growth startups and private market opportunities. The platform simplifies the investment process by providing access to early-stage investment opportunities that were once limited to venture capitalists and institutional investors. MicroVentures generates revenue through a dual-fee structure, where investors pay a fee based on their investment amount, and companies pay a fee to list their fundraising campaigns. Additionally, the company offers educational resources to help investors understand the risks and make informed decisions about equity crowdfunding. This focus on accessibility and education sets MicroVentures apart from its competitors in the fintech market.
Company Size
51-200
Company Stage
N/A
Total Funding
$3.2M
Headquarters
Austin, Texas
Founded
2009
Simplify's Take
What believers are saying
- Growing interest in sustainable housing solutions presents new investment opportunities for MicroVentures.
- The rise of 3D printing in healthcare offers potential investment avenues for MicroVentures.
- Anfin's success in democratizing stock investing aligns with MicroVentures' mission.
What critics are saying
- Increased competition from new crowdfunding platforms could attract investors away from MicroVentures.
- Decentralized finance platforms pose a threat to traditional equity crowdfunding models.
- Regulatory scrutiny on equity crowdfunding platforms may increase operational costs.
What makes MicroVentures unique
- MicroVentures connects both accredited and non-accredited investors with early-stage startups.
- The platform offers a dual-fee structure, generating revenue from both investors and companies.
- MicroVentures provides educational resources to help investors understand equity crowdfunding risks.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Company Equity
Performance Bonus
Company News
Oakland-based Mighty Buildings, which is on a quest to build homes using 3D printing, robotics and automation, has raised a $22 million extension to its Series B round of funding. The company claims to be able to 3D print structures “two times as quickly with 95% less labor hours and 10-times less waste” than conventional construction. For example, it says it can 3D print a 350-square-foot studio apartment in just 24 hours.
3D Printed Biodegradable Mesh Designed to Deliver Cancer Drugs Directly to Tumor Site With Greater Efficacy, Reduced Side Effects
ICON, in one of the largest seed rounds for Texas start-ups in 2018, announces $9M in funding.
Rochester, MN | February 10, 2023 – Pneumeric Inc., developers of the Capnospot™ - A disposable medical device that allows visual detection of carbon dioxide during treatment of a collapsed lung with needle decompression, has raised nearly $40,000 from 124 investors through its recently launched equity crowdfunding campaign. These funds build on the $1.2 million Pneumeric has
BOSTON, Aug. 15, 2022 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, today announced that it has closed more than $2.3M in its expanded seed round financing. Funding from the raise is being used to study Remedium's lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders. The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels. Potential to reverse years of age-related cartilage loss Tweet this We believe that any disease can be cured. - Remedium Bio